51, 28, and 3 transplantation respectively. Bone marrow plus cord blood were used in one patient. All donors were HLAidentical, 64 were siblings and 7 were parents. Conditioning regimens consisted of BU+CY (60 patients) , BU+CY+ATG (15 patients), BU + Thiotepa + CY (4 patients), TLI+ATG (1 patient), ATG (1 patient) and Pesaro Protocol 26 in 2 patients . All patients received CsA and /or MTX or prednisolon for GVHD prophylaxis. Engraftment was achieved in all patients. Median neutrophile engraftment time was 15 days and platelet engraftment time was 24 days. We observed acute GVHD in 16 patients (22.53%) and chronic GVHD in 3 patients. Graft rejection was seen in a total of 19 transplants (5 to 18 mos after SCT), 16 with recurrence of thalassemia and 3 with aplasia. Second SCT was performed in 12 patients. Median age was 8 y and eight of them Class II and four patients were Class III. Median interval between rejection and second transplantation was 12 months in second transplantation group. Sources of stem cell were BM in eight and peripheral blood in four patients. Six patients cured in this group. Of the 13 patients who died (18.3%), causes of death were infection in 8 , hemorrhage in 3 patients, VOD in one a nd interstitial pneumonia in one patient. In our series; event free survival was found as 62% and overall survival 81.70%. We conclude that stem cell transplantation is the only curative treatment method for thalassemic children who have HLA-identical siblings or parents.
O360
Favorable outcome of stem cell transplantation in severe thalassemia with alternative donors: matched unrelated and haploidentical donors S. Hongeng, S. Pakakasama, A. Chuansumrit, N. Sirachainunt, P. Tardtong, P. Kraiphibul, S. Jootar (Bangkok, TH) Allogeneic BMT from HLA-identical family donors is the onyl curative procedure for thalassemia (thal). However, only 30% of these patients can have matched sibling donors available. Recent data reported that event free survival of matched unrelated donor (MUD) transplant in thalassemia was 69% (n=32). Between March 2001 and November 2002, 12 thalassemia patients (pts) were included in this study. Eight were male; 4 female. Age ranged between 2 yrs and 18 yrs (median; 7yrs). Six had beta thal major and six had beta thal/HbE. Eleven received MUD transplant and one received haploidentical transplant (CD34+ purification method). The conditioning regimen of MUD transplant consisted of busulfan (16mg/kg), cyclophosphamide (200mg/kg), and ATG (Fresinius) 60mg/kg. The conditioning of haploidentical transplant consisted of busulfan (8mg/kg), thiotepa (5mg/kg), fludarabine (200mg/m2), ATG(25mg/kg), and TLI 500cGy). GVHD prophylaxis was with cyclosporin and mycophenolate mofetil (MMF)in 7 pts, FK506 and MTX in 3 pts, and FK506 and MMF in 2 pts. Neutrophil engraftment was achieved at day +14, platelet engraftment was achieved at day+ 60. Eight pts had acute GVHD grI-II and none had acute GVHD grIII-IV. One had chronic GVHD (limited). All pts (100%) survived without disease with median follow up time 1yr. Chimerism study demonstrated full donor chimerism (100%) in all pts.
Oral Session: Aplastic anemia
O361
The type of graft-versus-host disease prophylaxis influences the degree of hematopoietic chimeraism following allogeneic bone marrow transplantation for severe aplastic anaemia -a comparison between cyclosporine and cyclosporine and methotrexate S. McCann, M. Lawler, F. Locatelli, A. Locasciulli, B. Bruno, J. Passweg, H. Schrezenmeier Locatelli et all demonstrated a survival advantage for patients with severe aplastic anaemia receiving a sibling allograft who received cyclosporine(Csa) and methotrexate (Mtx) over cyclosporine alone as prophylaxis against Graft versus Host Disease (GvHD). This study was undertaken on a sub group to determine if the type of GvHD prophylaxis influenced the degree of haemopoietic chimaerism. Forty seven patients who received bone marrow from sibling donors and survived > 14 days were studied on at least three occasions (3-15) following transplant. Twenty two received Csa and 25 Csa and Mtx. Peripheral blood or bone marrow slides were evaluated for informative polymorphisms using PCR of short tandem repeats. Informative polymorphisms were detected in all pairs and results were interpreted without knowledge of the type of prophylaxis given. Patients were followed 44-130 months after transplant. Four groups were identified, complete donor chimeras, transient mixed chimeras, stable mixed chimaeras and progressive mixed chimeras. Six (13%) patients had graft failure, 3 prior to day 20 and three subsequently. Three are alive, 2 with autologous recovery and one had a second transplant. The cell dose given was critical in determining the probability of graft failure. MNC of 1.1-3.3 x 108/kg was associated with a probability of 0.33 whereas the probability with a cell dose >5.6 was 0.001. Csa and Mtx were associated with a higher incidence of donor and transient mixed chimaerism (p<0.05) and patients receiving the two drugs experienced more chronic GvHD (p<0.05). There was no difference in the incidence of progressive mixed chimaerism in either group. Patients who were stable mixed chimaeras never experienced chronic GvHD irrespective of the prophylaxis. We conclude that a combination of Csa and Mtx is associated with an increased rate of complete donor chimerism and a higher incidence of cGvHD following BMT for SAA. Locatelli F et al. Blood 1,2000 : 1690 -1697 .
O362
Long-term survival after transplantation for aplastic anemia: impact of previous treatment and of conditioning regimen L. Adès, J.-Y. Mary, M. Robin, A. Devergie, P. Ribaud, H. Esperou, E. Gluckman, G. Socié (Paris, F) This study included 133 patients (pts) who underwent allogeneic bone marrow transplantation (BMT) from an HLA identical sibling, after TAI-Cy (n=100) and Cy-ATG (n=33), respectively. Median follow-up was 12.6 years. There was 80 men and 53 women, median age was 19 years (4-46), 75 met criteria for SAA at diagnosis, 67 were first treated by immunosuppressive therapy +/-androgens before transplant. Median time from diagnosis to BMT was 300d (10d 10y); and 48 pts received more than 20 transfusions before BMT. Acute GvHD prophylaxis consisted in methotrexate (n=14), cyclosporine (n=44), cyclosporine and methotrexate (n=70), others (n=5). Bone marrow failure or rejection occurred in 9 patient. Both grade II-IV acute GvHD (42% vs. 0%, p<0.001) and chronic GvHD (5-year incidence 70% vs. 49%, p=.01) rates were increased following TAI. Avascular necrosis 5-year cumulative probability was 28% and 14% after Cy-ATG & Cy-TAI, respectively (p=0.05) . 10 solid tumors were diagnosed, 8 after TAI-Cy, 2 after ATG-Cy, leading to an overall 20-years probability of 23%. At 14 years, overall survival was 61%. Projected 10 years survival in 1 year survivors was 76% for TAI-Cy and 100% for ATG-Cy patients (p=.02). Infection with or without chronic GvHD was the most frequent cause of death (22/46). By univariate analysis, 10 years overall survival was significantly worsened by pre-treatment before grafting (50% vs. 79%, p=.007), interval from diagnosis to transplant of more than a 1 year (27% vs. 69%, p=.0004), conditioning using TAI-Cy (59% vs. 87%, p=.02). By multivariate analysis, including pretransplant characteristics (age, conditioning regimen, treatment before transplant, infection within 3 months preceding transplantation, GvHD prophylaxis, delay between diagnosis and transplantation, ABO incompatibility and severity of Aplastic Anemia (AA) at diagnosis) 2 factors were associated with worse outcome : previous treatment before transplant [relative risk =2.6 (95% CI; 1.3-5.2), p=.004] and TAI-Cy as conditioning regimen.
[relative risk =3.3 (95% CI; 1.2-9.3), p=01].
In conclusion, these results demonstrate that there is a significant reduction in the incidence of both acute and chronic GvHD with ATG-Cy conditioning regimen leading to a better overall survival and that previous treatment significantly affect long-term outcome before BMT for AA.
O363
Mycophenolate mofetil as treatment of patients with acquired aplastic anemia failing to durably respond to standard immunosuppressive treatment
Raghavachar, U. Reinold, H.J. Weh, E. Thiel, J. Passweg on behalf of the Aplastic Anemia Working Party
Standard regimen for immunosuppressive treatment of aplastic anaemia (AA) is a combination of antithymocyte globulin (ATG), steroids and ciclosporin A. 70-80% of patients respond to this treatment. There is no established standard for treatment of patients failing to respond to ATG-based regimen. Options for these patients are alternative donor stem cell transplantation, further cycles of ATG-based regimens or treatment with other immunosuppressive drugs, in particular drugs that inhibit proliferation of T cells and generation of cytotoxic T cells like MMF which is a potent, non-competitive, reversible inhibitor of inosine monophosphate dehydrogenase. Several studies in organ transplantation demonstrated that MMF can significantly reduce the rate of graft rejection and MMF has been successfully used to treat other autoimmune disorders including patients which were refractory to other immunosuppressive agents. Therefore we analyzed the effect of MMF in patients with acquired AA who did not durably respond to ATG treatment or were not eligible for ATG treatment due to serious adverse events of ATG. We report on 14 patients (9 males, 5 females) with a median age of 49.5 years, who failed to respond to previous ATG treatment (n=9), relapsed after previous ATG treatment (n= 3) or were ineligible for ATG due to adverse events or concomitant diseases (n=2). The median interval between diagnosis and start of MMF treatment in these patients was 29.3 months. According to the protocol MMF should be given at a dose of 2000 mg per day (divided in two doses) for at least 120 days as a single agent treatment. 9 patients were treated for at least 90 days. In 4 patients MMF was stopped early due to adverse events (diarrhea in one patient, gastric bleeding in one patient and infections in two patients after 76, 25, 42 and 38 days, resp.). Six patients experienced infections. In two of these cases MMF treatment was finally terminated. In the other cases MMF was continued and infections resolved. None of the 12 patients who were treated for at least 28 days and none of the 9 patients who were treated for at least 3 months showed durable response (in one patient transient PR was observed after 56 days). In summary, we did not observe durable response to MMF in this small cohort of patients with refractory or relapsed SAA. Gy was used in 3 pts with unrelated donors. One syngeneic pt received no conditioning at all. The following donors were used: HLA-identical siblings n=32, HLA-mismatched family donors n=1, syngeneic twins n=2, , matched unrelated donors n=4. GVHD prophylaxis consisted of cyclosporine A alone (CsA) n=8, CsA+MTX n=18, CsA+MTX+steroids n=4, CsA+Campath 1M n=1 or ex-vivo T cell depletion (CliniMACS device) n=7. Additional graft rejection prophylaxis with antithymocyte globulin was performed in 11 pts. As stem cell source we used bone marrow n=32 and peripheral blood stem cells n=7. Results: Overall survival (OS) after 19 y is 81%, there is no significant difference between the OS of SAA and PNH (79% vs 85%); only 1 pt showed graft rejection with consecutive autologous regeneration. No relapses were observed, transplant related mortality (TRM) was 19% with no significant difference between SAA and PNH (21% vs 14%). The actuarial risk of developing acute GVHD II-IV° and chronic GVHD was 23% and 50% respectively. Treatment results have improved over time with no fatalities observed after 1994.
Conclusions: These data demonstrate that allogeneic SCT is a highly effective treatment option for younger pts with vSAA and SAA and provides an excellent long-term outcome.The results for pts with PNH are equally good.
O365
Unrelated versus sibling transplant donors in aplastic anemia, results from Huddinge University Hospital C. Löfgren, J. Aschan, B. Gustafsson, O. Ringden, J. Winiarski, P. Ljungman (Stockholm, S) Since 1975, 57 patients with SAA have recieved stem cell transplants at Huddinge University Hospital. We hereby report the results comparing the effect of unrelated and sibling donor allografts. HLA identical siblings (HLAsib) were donors for 37 patients and 17 patients received allografts from unrelated donors (MUD). Three patients were transplanted with other types of related donors and not further analysed. Different features of the patients with SAA are shown in table 1. The median age of all patients was 17 (1-55). Fourteen patients failed ATG-treatment prior to SCT and ten patients were transplanted without receiving any treatment for aplastic anemia, the rest received a variety of steroid containing therapies. Cyclophosphamide containing conditioning regimen was given to 34 and 14 patients prior to HLAsib or MUD SCT, respectively, another three patients received fludarabine prior to SCT with MUD. After SCT acute GVHD developed in 19 patients with HLAsib and in 10 patients with MUD. The estimated 10 year survival was 82% in patients with HLAsib donors and 49% with MUD. Fig1. Patients (<17years), developement of acute GVHD and donor type (HLAsib or MUD), were significant for survival, where as patient gender, CMV status and previous treatment were not. Three patients rejected their allografts and were retransplanted, one is alive. Five patients have become parents (two female). Two separate cases of squamous cell carcinoma in the oral cavity and one case of basalioma of the skin are reported.
O366
The suppressive effect of normal bone marrow stroma on Tcell activation is deficient in patients with aplastic anemia M.T. Valle, M. Podestà, G. Piaggio, A. Pitto, F. Vassallo, S. Luchetti, O. Figari, F. Frassoni, M.T. van Lint, A. Bacigalupo (Genoa, I) Background. Mesenchymal stem cells (MSC) exhibit immunosuppressive effect in vitro and in vivo both in humans (Blood 2002; 99:3838) and primates (Exp Hematol 2002; 30: 42) . This may suggest an immunoprotective effect of MSC on stem cells. Objectives. In this study we compare the effect MSC from normal individuals and patients with aplastic anemia (SAA) on T cell activation in vitro, to test for possible differences. Methods. MSC were obtained by adherence of bone marrow light density cells, expanded for 3 generations and then incubated with normal peripheral blood mononuclear cells exposed either to alloantigens, in a mixed lymphocyte reaction (MLR), or to phytohemagglutinin (PHA). Results. The addition of normal MSC stromal cells produced a dose dependent suppressive effect of MLR, ranging from 10% with 6x10^3 cells, to 100% with 100x10^3. A mouse stromal cell line (M210-B4) also exhibited suppressive effect on MLR (21% to 73% with 100x10^3 cells). The suppressive effect was shown both when using human MSC cells or their supernatant. Expression of CD38 on PHA blasts was down regulated by MSC (6% vs 81% CD38+ cells in cultures with or without MSC). When PHA blasts were washed from MSC supernatant and cultured for 3 days, the suppressive effect was lost. MSC from SAA patients (n=5) failed to exhibit MLR suppression, which ranged from 6% with 25x 10^3 to a maximum of 26% with 100x10^3 cells, and was significantly lower (p<0.01) than normal controls at all cell concentrations tested. Similarly SAA MSC failed to inhibit PHA priming, with suppression ranging from 16% to 34% , again significantly different compared to controls (p<0.01). Conclusions. This study confirms a strong inhibitory activity of normal MSC on T -cell activation. The effect is non HLA restricted, non species specific , it is reversible and can be mediated via soluble factors. The capacity of MSC to down regulate T cell function is deficient in patients with aplastic anemia, and it is tempting to speculate that this may play a role in the pathogenesis of marrow failure.
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A possible role for HLA epitope analysis in the avoidance and treatment of platelet resistance G. Laundy, B. Rees, C. Spink, M. Younie, L. Keen, H. Schrezenmeier, J. Marsh, B. Bradley, J. Hows (Bristol, UK; Ulm, D; London, UK) Transfusion induced platelet resistance (PR) in acquired aplastic anaemia (AAA) is associated with considerable morbidity. We have established the extent of lymphocyte humoral alloimmunity in a cohort of patients with AAA and investigated whether epitope analysis could identify the immunodominant epitopes responsible for the development of PR. 150 AAA patients (3 days to 22 years post-transfusion) from 8 European centres have been extensively screened for antibody by flow cytometry [FC] and complement dependent cytotoxicity [CDC] using donor panels carefully selected to include as many HLA class I alleles as possible. All patients were multiply transfused, the majority having received >100 units. Of 144 informative patients 89 (62%) w ere FC and/or CDC antibody (Ab) positive. 33 (23%) were FC+CDC-indicating weak HLA class I Ab, non-complement fixing Ab or HLA class II Ab. 35 patients (24%) were FC+CDC+ including 18 who had an IgM Ab component. 21 patients had IgM Ab alone, the majority of which were auto-reactive. Fifteen definable complement-fixing HLA class I antibodies (13 IgG, 2 IgM) were observed in 11 patients (3 male, 7 female, 1 unknown, sampled 27 to 3058 days posttransfusion [median 612 days]). Of these, 12 Ab reacted with HLA-A epitopes including 6 with specificity for HLA-A1/HLA-A1 associated cross-reactive group (CREG) epitopes. We identified a significant correlation between serum reactivity and simple amino acid substitutions associated with public epitopes on the HLA class I molecule (epitope analysis). For example, patient KG186, a multiparous female was PR due to Ab reactivity with 88% of the reference panel. The Ab activity correlated (p=1.2x10-9) with 2 postulated target epitopes: Arg163 (HLA-A1, A11, A25, A26, A43, A6601) and Lys127 (HLA-A2, A23, A24, A68, A69) and a complex epitope involving Lys44, Val150 and Val158 (HLA-A1, A36). We conclude that epitope analysis and avoidance could be used to provide cost-effective compatible platelets for patients with PR. Our results also suggest that PR could be prevented or reduced in approximately 30% of cases by provision of HLA-A1 negative platelets for HLA-A1 negative patients from the time of diagnosis.
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DNA microarray analysis of the FANC-C deficient cell line HSC536N: a tool to identify new genes involved in the pathogenesis of Fanconi's anemia group C P. Guardiola, P. Ladne, P. Kurre, J. Soulier, D. Hare, J. Delrow, F. Sigaux, H.P. Kiem, E. Gluckman, J.P. Radich (Seattle, USA; Paris, F) The FANC-C gene, besides its f unctions within the Fanconi anemia (FA) nuclear complex, has been shown to have some non-FANC cytoplasmic partners, suggesting an additional role of this gene in distinct metabolic pathways. In order to investigate the broad-spectrum involvement of the FANC-C gene in cellular functions we used oligonucleotide array analysis of 36000 known genes and ESTs using Affymetrix microarray platforms. dChip software 1.3 was used to determine differential gene expression patterns between HSC536N, a FANC-C deficient cell line (Cw), and its homologue corrected by retroviral insertion of the FANC-C gene (Cneo), under normal culture conditions and after incubation with mitomycin C (MMC) at 100 nM. Under normal culture conditions, 73 genes were consistently induced (Cw > Cneo) and 34 genes were repressed (Cw < Cneo) by greater than 2-fold in Cw compared to Cneo. Among the up-regulated genes were pro-apoptotic genes (CASP1, TMS1); MIC1 (a p53-transcriptionally regulated gene); cyclin G2; HSPA1A; ADA; melanoma antigens and THIF. Included in the group of downregulated genes were FOXO1A (an AFX family member that transcriptionally activates Kip1); p63; annexin V; and CD23 a key molecule for B-cell activation and growth. Among the genes that were differentially expressed in Cw but not in Cneo after incubation with MMC, were HK2 (a key enzyme for glucose metabolism); DDB2 a potential link between p53 and the nucleotide excision-repair apparatus; GADD45A involved in DNA repair and S phase entry, and MIC1. Finally, after incubation with MMC, 156 genes demonstrated consistent differential expression between Cw and Cneo. Among the repressed genes were FOXO1A; p63; annexin V; CD23; and TOSO a negative regulator of apoptosis. Cyclin G2; CASP1; MIC1; ADA; HSPA1A; THIF; melanoma antigens and REDD1 (a transcriptional target of p53 up-regulated following DNA damage involved in regulation of ROS) were at higher levels of expression in Cw after MMC exposure. These preliminary data have enabled us to identify new genes that may be involved in FA pathogenesis. The increased level of expression of genes involved in ROS metabolism (ADA, REDD1, THIF) in Cw underlies the importance of this metabolic pathway in FANC-C. Extrapolation of these results on a "leukemic" tetraploide HSC536N cell line as well as on FANC-A, -G, -D2 deficient cell lines and patient samples are under investigation.
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Allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukemia using reduced-intensity conditioning: interim results of a prospective study P. Dreger, S. Stilgenbauer, D. Bunjes, A. Humpe, M. Ritgen, B. Seyfarth, L. Truemper, M. Kneba, N. Schmitz, H 
. Doehner on behalf of the German CLL Study Group
Allogeneic stem cell transplantation (SCT) might be an option in resistant chronic lymphocytic leukemia (CLL) since this disease is known to be sensitive to graft-versus-leukemia (GVL) effects. However, allografting for CLL using conventional conditioning has been associated with an extremely high treatment-related mortality (TRM). In order to avoid toxicity but take advantage of GVL activity, we have studied allotransplantation in CLL using an reduced-intensity conditioning (RIC) regimen containing fludarabine (F) and cyclophosphamide (C). 18 patients with symptomatic CLL relapsing after fludarabine or equivalent high risk features were eligible. Median age was 52 (40-63) years. Previous therapy comprised 3 (1-7) regimens. PBSC grafts were obtained from HLA-identical related (n=14) or unrelated donors (n=4). Conditioning consisted of daily F 30mg/m² and C 500mg/m² over 5 days; GVHD prophylaxis was performed with CSA/short-course MTX or CSA/MMF. In case of unrelated donors, ATG was added. Donor lymphocyte infusions (DLI) were administered from day +100 onwards in case of incomplete chimerism or residual disease. Results: Hematopoietic recovery occurred in all patients with a median time to neutrophil recovery of 15 (7-28) days and a median number of 2 (0-37) transfused platelet units. At least transient partial or complete (>95%) hematopoietic donor chimerism was observed in all 17 patients evaluable for this endpoint (including 3 patients receiving DLI): The probability of being a complete chimera was 44% at 3 months and 93% at 12 months post transplant. Early nonhematological toxicity was very low, and severe acute GVHD occurred in only 2 patients. The 12-month estimate of chronic GVHD was 69% (95%CI 45-93%). With 16 (1-40) months of follow-up, 2-year event-free survival and TRM were 88% and 6%, respectively. Molecular remission as defined by polyclonal consensus primer CDR3 PCR was achieved by 9 of 11 evaluable patients after a median time of 7 (1-11) months post SCT. Conclusions: The RIC regimen used here promises to improve the outcome after allogeneic SCT for poor-risk CLL by reducing TRM while preserving significant GVL activity.
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Sibling and unrelated reduced-intensity conditioned allogeneic transplantation for chronic myeloid leukemia C. Crawley, R. Szydlo, M. Lalanacette, A. Bacigalupo, A. Lange, G. Juliusson, A. Shimoni, A. Nagler, A. Gratwohl, J. Mayer, O. Ringden, J-M Boiron, G. Smith, D. Niederwiesser, J 
. Apperley for the Chronic Leukaemia Working Party of the EBMT
Reduced intensity conditioned (RIC) allografts have been widely adopted in haemopoetic transplant programmes over the last 5 years despite limited evidence of efficacy with the majority of series reporting a variety of diseases and/or small numbers. 39 EBMT centres reporting more than 5 RIC allografts for CML or myeloma between 01/94 and 09/02 were contacted and data on all procedures performed in those centres were collected on a total of 225 transplants. The M:F ratio was 1.6:1 and the median age was 50 yrs (13-66). 134 were matched siblings, 65 were unrelated and the remainder were from mismatched or other related donors. 62% were in 1st CP, 14% 2nd CP, 17% AP and 7% in blast crises. The median time to transplant was 15 months (2 months-21 years). Conditioning regimens included fludarabine (74%), cyclophosphamide (30%), busulphan (41%), melphalan (19%) and campath/ATG (49%). Total body irradiation was used in 17% with a median dose of 2.0 Gy. The source of cells was bone marrow (BM) in 72 patients and peripheral blood stem cells (PBSC) in 152. Median cell doses for BM were 3.8 x10^8 MNC/kg and 5.8x10^6 CD34/kg for PBSC. Neutrophil and platelet engraftment occurred at median of 16 and 17 days respectively and the non engraftment rate was 8%. GvHD prophylaxis consisted of cyclosporin in 50% with additional methotrexate in 45%. Acute GvHD (grade II-IV) occurred in 29.5% but grade III-IV was limited to 8.1%. Chronic GvHD occurred in 72/122 and was extensive in 25.4%.. Chimaerism (>95% donor) was achieved in 80.4% at best but had fallen to 77% at last follow up (data on 107 patients, median follow up 420 days). Overall the treatment-related mortality was at 1 year was 22%. Progression occurred in 39%. With a median follow up of 342 days overall survival at two years was 55%. Factors associated with a poor outcome at 2 yrs were, disease phase 1st CP, 2nd CP or AP/BC survival was 66%, 61%, 21% respectively (p= 0.0001) and time to transplant > 1 yr, 65% vs 44% (p=0.01). Age, donor type, source of cells and the female donor-male recipient combination were not associated with an adverse outcome. There was a trend to worse outcome with male sex (51% vs 61%, p=0.11). This study confirms the feasibility of RIC allografts and the acceptable TRM. The survival at two years is in keeping with conventional allogeneic transplantation despite the older age.
